Profile data is unavailable for this security.
About the company
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-139.79m
- Incorporated2016
- Employees143.00
- LocationAdicet Bio Inc131 Dartmouth Street, 3Rd FloorBOSTON 02116United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (302) 655-5049
- Websitehttps://www.adicetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allovir Inc | 0.00 | -179.53m | 84.53m | 112.00 | -- | 0.7011 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 85.05m | 9.00 | -- | 4.31 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 87.70m | 22.00 | -- | 0.973 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.06m | -29.36m | 89.45m | 39.00 | -- | 0.7827 | -- | 84.07 | -2.12 | -2.12 | 0.055 | 4.23 | 0.0147 | -- | -- | 27,282.05 | -40.57 | -62.84 | -43.48 | -68.03 | -- | -- | -2,759.59 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 89.57m | 143.00 | -- | 0.3461 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Annovis Bio Inc | 0.00 | -47.53m | 90.27m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 90.82m | 20.00 | -- | 1.26 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 90.87m | 8.00 | -- | 2.69 | -- | 14.83 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 90.95m | 10.00 | -- | 0.4787 | -- | 45.48 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 91.47m | 66.00 | -- | -- | -- | 19.47 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 92.99m | 46.00 | -- | 0.7877 | -- | 5.73 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Boundless Bio Inc | -100.00bn | -100.00bn | 94.36m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 94.66m | 126.00 | -- | 0.7235 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 94.73m | 20.00 | -- | 0.8158 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 94.80m | 93.00 | -- | 91.51 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Clearside Biomedical Inc | 8.45m | -34.97m | 94.91m | 30.00 | -- | -- | -- | 11.23 | -0.543 | -0.543 | 0.1321 | -0.2919 | 0.1993 | -- | -- | 281,733.30 | -82.44 | -63.57 | -94.63 | -81.77 | 93.08 | -- | -413.72 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Data as of Jul 03 2024. Currency figures normalised to Adicet Bio Inc's reporting currency: US Dollar USD
55.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 31 Mar 2024 | 6.41m | 7.80% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 6.18m | 7.52% |
| RA Capital Management LPas of 09 Apr 2024 | 6.14m | 7.47% |
| Commodore Capital LPas of 09 Apr 2024 | 4.25m | 5.17% |
| RTW Investments LPas of 31 Mar 2024 | 4.13m | 5.03% |
| Millennium Management LLCas of 31 Mar 2024 | 4.11m | 5.00% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 4.04m | 4.91% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 3.80m | 4.62% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.14m | 3.82% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.09m | 3.76% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
